US biopharmaceutical company AbbVie Inc on Tuesday said that it would buy Botox-maker Allergan PLC for about US$63 billion, moving to diversify its product line as the industry faces pressure on drug prices.
The deal, the latest large transaction in pharma, broadens the product offerings for AbbVie, which has relied heavily on sales of Humira, a drug to treat rheumatoid arthritis that faces rising competition from generics.
Combining operations would allow annual savings of at least US$2 billion through trimming duplicative research and development spending and cuts in sales and marketing spending, the companies said in a statement. The deal is expected to close early next year.
“This is a transformational transaction for both companies and achieves unique and complementary strategic objectives,” AbbVie CEO Richard Gonzalez said in a statement. “With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie’s business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future.”
Allergan, which is based in Ireland, is best known for Botox, which reduces face wrinkles. The company specializes in the areas of medical aesthetics, eye care, central nervous system and gastroenterology.
Allergan, which grew quickly earlier in this decade, has faced pressure from Wall Street, in part due to worries over the hit from patent expirations of eye medication Restasis. Some analysts have called for the firm to be broken up.
The companies would have a combined annual revenue of US$48 billion and a presence in 175 countries, the statement said.
“This acquisition creates compelling value for Allergan’s stakeholders, including our customers, patients and shareholders,” Allergan CEO Brent Saunders said.
The offer represents a 45 percent premium over Monday’s share price of Allergan, whose management recommended the operation to shareholders.
Shares of Allergan on Tuesday surged 25.4 percent to US$162.43, while AbbVie fell 16.3 percent to US$65.70.
AbbVie has faced questions over patent expirations for Humira, which accounted for more than 60 percent of its revenue of US$32.7 billion last year.
Allergan made more sense to buy than some smaller targets with promising drugs under development, because it “meets our strategic goal to reduce reliance on Humira and allows us to continue expanding our focus on high-innovation science throughout the next decade,” Abbvie said.
“Smaller bolt-on acquisitions provide opportunities for future growth, but also require significant research and development investment amid scientific and clinical uncertainty,” the company added.
A report from Moody’s Investors Service earlier this month predicted more mergers in the pharma industry, citing the effect of patent expirations and a 2017 US tax reform that eased the burden of companies that take on debt for acquisitions.
The report also pointed to stepped-up pressure on drug manufacturers within the healthcare industry on pricing, “as well as the public backlash associated with implementing large price increases.”
SEEKING CLARITY: Washington should not adopt measures that create uncertainties for ‘existing semiconductor investments,’ TSMC said referring to its US$165 billion in the US Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) told the US that any future tariffs on Taiwanese semiconductors could reduce demand for chips and derail its pledge to increase its investment in Arizona. “New import restrictions could jeopardize current US leadership in the competitive technology industry and create uncertainties for many committed semiconductor capital projects in the US, including TSMC Arizona’s significant investment plan in Phoenix,” the chipmaker wrote in a letter to the US Department of Commerce. TSMC issued the warning in response to a solicitation for comments by the department on a possible tariff on semiconductor imports by US President Donald Trump’s
‘FAILED EXPORT CONTROLS’: Jensen Huang said that Washington should maximize the speed of AI diffusion, because not doing so would give competitors an advantage Nvidia Corp cofounder and chief executive officer Jensen Huang (黃仁勳) yesterday criticized the US government’s restrictions on exports of artificial intelligence (AI) chips to China, saying that the policy was a failure and would only spur China to accelerate AI development. The export controls gave China the spirit, motivation and government support to accelerate AI development, Huang told reporters at the Computex trade show in Taipei. The competition in China is already intense, given its strong software capabilities, extensive technology ecosystems and work efficiency, he said. “All in all, the export controls were a failure. The facts would suggest it,” he said. “The US
The government has launched a three-pronged strategy to attract local and international talent, aiming to position Taiwan as a new global hub following Nvidia Corp’s announcement that it has chosen Taipei as the site of its Taiwan headquarters. Nvidia cofounder and CEO Jensen Huang (黃仁勳) on Monday last week announced during his keynote speech at the Computex trade show in Taipei that the Nvidia Constellation, the company’s planned Taiwan headquarters, would be located in the Beitou-Shilin Technology Park (北投士林科技園區) in Taipei. Huang’s decision to establish a base in Taiwan is “primarily due to Taiwan’s talent pool and its strength in the semiconductor
French President Emmanuel Macron has expressed gratitude to Hon Hai Precision Industry Co (鴻海精密) for its plan to invest approximately 250 million euros (US$278 million) in a joint venture in France focused on the semiconductor and space industries. On his official X account on Tuesday, Macron thanked Hon Hai, also known globally as Foxconn Technology Group (富士康科技集團), for its investment projects announced at Choose France, a flagship economic summit held on Monday to attract foreign investment. In the post, Macron included a GIF displaying the national flag of the Republic of China (Taiwan), as he did for other foreign investors, including China-based
RSS